SominoneCAS# 98569-64-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 98569-64-3 | SDF | Download SDF |
PubChem ID | 44249449 | Appearance | Powder |
Formula | C28H42O5 | M.Wt | 458.63 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R)-2-[(1S)-1-[(1S,3R,8S,9S,10R,13S,14S,17R)-1,3-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-4-methyl-2,3-dihydropyran-6-one | ||
SMILES | CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC=C5C4(C(CC(C5)O)O)C)C)CO | ||
Standard InChIKey | FYYIHVSEGVWNCF-RMDUJBCISA-N | ||
Standard InChI | InChI=1S/C28H42O5/c1-15-11-24(33-26(32)20(15)14-29)16(2)21-7-8-22-19-6-5-17-12-18(30)13-25(31)28(17,4)23(19)9-10-27(21,22)3/h5,16,18-19,21-25,29-31H,6-14H2,1-4H3/t16-,18+,19-,21+,22-,23-,24+,25-,27+,28-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice. 2. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET. |
Targets | Beta Amyloid |
Sominone Dilution Calculator
Sominone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1804 mL | 10.902 mL | 21.8041 mL | 43.6081 mL | 54.5102 mL |
5 mM | 0.4361 mL | 2.1804 mL | 4.3608 mL | 8.7216 mL | 10.902 mL |
10 mM | 0.218 mL | 1.0902 mL | 2.1804 mL | 4.3608 mL | 5.451 mL |
50 mM | 0.0436 mL | 0.218 mL | 0.4361 mL | 0.8722 mL | 1.0902 mL |
100 mM | 0.0218 mL | 0.109 mL | 0.218 mL | 0.4361 mL | 0.5451 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Chloro-6-iodoquinazoline
Catalog No.:BCC8703
CAS No.:98556-31-1
- Methyl 2-bromomethyl-3-nitrobenzoate
Catalog No.:BCC9035
CAS No.:98475-07-1
- Pseudoginsenoside RT5
Catalog No.:BCN1076
CAS No.:98474-78-3
- Pseudoginsenoside RT1
Catalog No.:BCN2794
CAS No.:98474-74-9
- Myelin Basic Protein (68-82), guinea pig
Catalog No.:BCC1020
CAS No.:98474-59-0
- Metoprolol Succinate
Catalog No.:BCC6519
CAS No.:98418-47-4
- Finasteride
Catalog No.:BCC2491
CAS No.:98319-26-7
- Nodulisporic acid C2
Catalog No.:BCC8326
CAS No.:
- Boc-D-3-Pal-OH
Catalog No.:BCC2652
CAS No.:98266-33-2
- Boc-D-2-Pal-OH
Catalog No.:BCC2654
CAS No.:98266-32-1
- Isotanshinone II
Catalog No.:BCN3002
CAS No.:98249-39-9
- Hupehenine
Catalog No.:BCN2617
CAS No.:98243-57-3
- Cryptanoside A
Catalog No.:BCN7481
CAS No.:98570-81-1
- Schisandrone
Catalog No.:BCN3316
CAS No.:98619-25-1
- (S)-(-)-Bay K 8644
Catalog No.:BCC7108
CAS No.:98625-26-4
- Sarmentocymarin
Catalog No.:BCN7489
CAS No.:98633-61-5
- Nitrocaramiphen hydrochloride
Catalog No.:BCC6655
CAS No.:98636-73-8
- Zedoarondiol
Catalog No.:BCN3560
CAS No.:98644-24-7
- Methyl ganoderate H
Catalog No.:BCN3258
CAS No.:98665-11-3
- Ganoderic acid F
Catalog No.:BCN3037
CAS No.:98665-14-6
- Ganoderic Acid J
Catalog No.:BCN8436
CAS No.:100440-26-4
- Lucidenic acid D2
Catalog No.:BCN8202
CAS No.:98665-16-8
- Ganoderic acid H
Catalog No.:BCN3038
CAS No.:98665-19-1
- Ganoderic acid I
Catalog No.:BCN2865
CAS No.:98665-20-4
Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD.[Pubmed:21329473]
Int J Neurosci. 2011 Apr;121(4):181-90.
Previously we showed that steroidal sapogenin, Sominone improved memory after a single i.p. injection into normal mice. However, it had not been reported that Sominone could recover memory deficits in a severe Alzheimer's disease (AD) model animal. Therefore, we aimed to investigate that Sominone improved memory impairments in the 5XFAD mouse, model for AD. In the current study, we used Sominone that we had synthesized. 5XFAD mice were given 10 mumol/kg Sominone intraperitoneally for 9 days. In addition to object recognition memory, axonal density, amyloid plaque number, and activated microglia in the brain were evaluated. Sominone treatment significantly improved object recognition memory compared with vehicle control treatment. Sominone treatment significantly enhanced axonal densities in the frontal cortex and parietal cortex but had no effects on amyloid plaque number and activated microglia. In cultured cortical neurons, the axonal length was significantly reduced by Abeta(1-42) treatment. However, that was markedly recovered 5 days after the treatment with 1 muM Sominone. Neuronal loss was not observed in the cortex and hippocampus of 5XFAD mice at 6-8 months of age. These results suggest that memory deficits in AD may be improved by Sominone independently of reducing amyloid plaques and neuroinflammation.
Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET.[Pubmed:19594760]
Br J Pharmacol. 2009 Aug;157(8):1427-40.
BACKGROUND AND PURPOSE: Orally administered withanoside IV (a compound isolated from the roots of Withania somnifera) improved memory deficits in mice with a model of Alzheimer's disease induced by the amyloid peptide Abeta(25-35). Sominone, an aglycone of withanoside IV, was identified as an active metabolite after oral administration of withanoside IV. We aimed to identify receptors or associated molecules of Sominone, and to investigate the effects of Sominone on memory in normal mice. EXPERIMENTAL APPROACH: Phosphorylation levels of 71 molecules were compared between control and Sominone-stimulated cortical cultured cells to search for target molecules of Sominone. Object location memory and neurite density in the brain were evaluated in Sominone-injected mice. KEY RESULTS: Phosphorylation of RET (a receptor for the glial cell line-derived neurotrophic factor, GDNF) was increased in neurons by Sominone, without affecting the synthesis and secretion of GDNF. Knockdown of RET prevented Sominone-induced outgrowths of axons and dendrites. After a single i.p. injection of Sominone into normal mice, they could better memorize scenery information than control mice. Sixty minutes after Sominone injection, RET phosphorylation was increased, particularly in the hippocampus of mice. After the memory tests, the densities of axons and dendrites were increased in the hippocampus by Sominone administration. CONCLUSIONS AND IMPLICATIONS: Sominone could reinforce the morphological plasticity of neurons by activation of the RET pathway and thus enhance memory. Sominone, a compound with low molecular weight, may be a GDNF-independent stimulator of the RET pathway and/or a novel modulator of RET signalling.
Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration.[Pubmed:16553605]
Eur J Neurosci. 2006 Mar;23(6):1417-26.
At the present, medication of dementia is limited to symptomatic treatments such as the use of cholinesterase inhibitors. To cure dementia completely, that is regaining neuronal function, reconstruction of neuronal networks is necessary. Therefore, we have been exploring antidementia drugs based on reconstructing neuronal networks in the damaged brain and found that withanoside IV (a constituent of Ashwagandha; the root of Withania somnifera) induced neurite outgrowth in cultured rat cortical neurons. Oral administration of withanoside IV (10 micromol/kg/day) significantly improved memory deficits in Abeta(25-35)-injected (25 nmol, i.c.v.) mice and prevented loss of axons, dendrites, and synapses. Sominone, an aglycone of withanoside IV, was identified as the main metabolite after oral administration of withanoside IV. Sominone (1 microM) induced axonal and dendritic regeneration and synaptic reconstruction significantly in cultured rat cortical neurons damaged by 10 microM Abeta(25-35). These data suggest that orally administrated withanoside IV may ameliorate neuronal dysfunction in Alzheimer's disease and that the active principle after metabolism is Sominone.